The Effect of Polycystic Ovary Syndrome on the Embryo Morphokinetics ( PCOS )

Sponsor
ShangHai Ji Ai Genetics & IVF Institute (Other)
Overall Status
Completed
CT.gov ID
NCT05438355
Collaborator
(none)
153
1
10
15.3

Study Details

Study Description

Brief Summary

Polycystic ovarian syndrome (PCOS) is a complex endocrine and metabolic syndrome which accounts for 75% of women with anovulatory infertility. The cause of infertility in PCOS is already unknown. Although efforts have been made, many PCOS patients turned out to have worse oocyte maturity and IVF outcomes. Time-lapse analysis of embryo development can detect the abnormal timeline and cleavage mode which may affect the embryo viability of PCOS. However, there are still some debates on the effect of PCOS on the early embryo development by time-lapse analysis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Method:

    A consecutive cohort of 153 infertile women attending In vitro fertilization (IVF) or Intra-cytoplasmic sperm injection (ICSI) treatment at Shanghai Ji Ai G-IVF institute was requited from March 2021 to December 2021. During the period, couples undergoing IVF/ICSI treatment were offered blastocyst culture to day 6 and time-lapse imaging (TLI) as part of a study evaluating parameters for embryo selection. Women aged < 38 years without endometriosis and with more than 6 oocytes retrieved were eligible. Patients were categorized in two groups. Women with regular menstrual cycles and no clinical signs of PCOS (non-PCOS) and women fulfilling the Rotterdam diagnostic criteria for PCOS detected by the presence of anovulation and polycystic ovaries (PCO), which was diagnosed by luteal-phase progesterone testing and trans-vaginal ultrasound, respectively. Biochemical parameters of androgen excess were included in the diagnosis when available, whereas subjective symptoms of androgen excess (acne, hirsutism, alopecia) were not included. Ethical approval Written informed consent was obtained from all patients before inclusion. Shanghai Ji Ai ethical Committees approved the study.

    Ovarian stimulation:

    Patients were treated with individual doses of gonadotropin, based on serum anti-mullerian hormone (AMH) and/or antral follicle count. Patients were stimulated by gonadotropin-releasing hormone (GnRH) antagonist protocol using rec-follicle stimulating hormone (FSH) or human menopausal gonadotropin (HMG) for stimulation according to clinical guidelines. A dose of 10,000 IU of human chorionic gonadotropin (hCG) was administered when at least 3 follicles measured ≥ 17 mm, and ultrasound guided oocyte retrieval was conducted 36 h later. Oocyte retrieval and ICSI/IVF Ovarian stimulation and oocyte retrieval were performed according to standard procedures. After fertilization, ICSI embryos were immediately placed in the time-lapse incubator (EmbryoScope™). IVF embryos were cultured for approximately 18 h in a conventional incubator. Before IVF embryos were transferred to the EmbryoScope, adhering cumulus cells were removed to ensure optimal image acquisition. In the EmbryoScope, all embryos were cultured until arrest or removal at day 6.

    Embryo assessment:

    All embryos with 2 pronuclei completing the first cleavage were annotated manually. The following parameters were annotated with time points: appearance and disappearance of 1st nucleus and 2nd nucleus after 1st division, 1st - third divisions and blastocyst. All time-points were normalized to first cleavage and treated as durations for further analysis in order to overcome the limitation of inexact starting points, and facilitate comparison between IVF and ICSI populations. For the same reason, no parameters before first cleavage were investigated. Durations of cell cycles and cell stages were subsequently calculated as the interval between two time-points. Two parameters (multi-nucleation and direct cleavage to 3-cell stage) were assessed by binary values yes and no. Embryos were selected for transfer according to conventional measures of morphological quality on day 6 according to the Gardner criteria. No time-lapse parameters were used in the selection process. The observer was blinded to the patient's treatment data and medical history.

    Statistics:

    The influence of PCOS on embryo development was tested in regression models for clustered data. A covariance regression model was used to account for potential confounding variables: female age, BMI and fertility treatment. In total, 768 embryos from 80 PCOS women, and 676 embryos from 73 non-PCOS women were analyzed.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    153 participants
    Observational Model:
    Cohort
    Time Perspective:
    Cross-Sectional
    Official Title:
    The Effect of Polycystic Ovary Syndrome on the Morphokinetics or Abnormalities on Early Embryonic Development: a Time Lapse Study
    Actual Study Start Date :
    Mar 1, 2021
    Actual Primary Completion Date :
    Dec 1, 2021
    Actual Study Completion Date :
    Dec 30, 2021

    Arms and Interventions

    Arm Intervention/Treatment
    The infertility women with PCOS

    Infertile women undergoing assisted reproduction were consecutively recruited at Ji Ai G-IVF institute from March 2021 to December 2021. Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved . Patients were divided in PCOS according to the Rotterdam criteria for PCOS, defined by the presence of anovulation and polycystic ovaries.

    The infertility women without PCOS

    Infertility women with fallopian tubal factor infertility and with normal menstrual cycles were undergoing IVF/ICSI cycles at Shanghai Ji Ai G-IVF institute from March 2021 to December 2021.Women aged < 38 years without endometriosis and more than 6 oocytes were retrieved.

    Outcome Measures

    Primary Outcome Measures

    1. Embryonic developmental timing [From fertilization until transfer at day 6]

      Embryonic developmental timing assessed by Time-lapse analysis

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    20 Years to 37 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Women aged < 38 years without endometriosis and with more than 6 oocytes retrieved were eligible.
    Exclusion Criteria:
    • All embryos with more or less than 2 pronuclei, and that did not undergo first cleavage were excluded

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ji Ai Genetics and IVF center Shanghai Shanghai China 200021

    Sponsors and Collaborators

    • ShangHai Ji Ai Genetics & IVF Institute

    Investigators

    • Study Chair: Xiaoxi Sun, PHD, Shanghai G-IVF institute

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    ShangHai Ji Ai Genetics & IVF Institute
    ClinicalTrials.gov Identifier:
    NCT05438355
    Other Study ID Numbers:
    • 2022JIAI-06
    First Posted:
    Jun 29, 2022
    Last Update Posted:
    Jul 6, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by ShangHai Ji Ai Genetics & IVF Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 6, 2022